Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
NCT07667400
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States. Survival rates for these cancers are lower than 50% if they spread to other parts of the body or return after treatment. Better treatments are needed. Objective: To test a new drug (SX-682), combined with an approved drug (docetaxel, or DTX), in people with HNCs or prostate cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma
- Paranasal Sinus Neoplasms
- Nasopharyngeal Carcinoma
- Oropharyngeal Squamous Cell Carcinoma
- Hypopharyngeal Cancer
- Carcinoma of Larynx
- Oral Squamous Cell Carcinoma
- Salivary Gland Cancer
- Adenoid Cystic Carcinoma
- Prostate Cancer
- Metastatic Castration Resistant Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 120 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- National Cancer Institute (NCI)
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- National Institutes of Health Clinical Center · Bethesda, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.